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Abstract 
Vaccine efficacy and mortality in successive cohorts of children who routinely received either Edmon- 
ston-Zagreb high-titre (EZ-HT) or Schwarz standard (SW-STD) measles vaccines have been examined in 
a rural area of Senegal. The 2 vaccines were equally protective against measles infection (vaccination effi- 
cacy: EZ-HT 94%; SW-STD 93%). Children who did not attend a scheduled session to receive measles 
vaccine had a higher mortality rate between 9 months and 2 years of age than did children receiving either 
EZ-HT (mortality ratio [MR] = 1*81,95% confidence interval [CI] 1.06-3.08) or SW-STD measles vaccine 
(MR=1.74, 95% CI 0.95-3.21). Children of either sex vaccinated with EZ-HT had lower mortality than 
their equivalents who had not received any measles vaccine. There was no difference in overall mortality 
between recipients of EZ-HT and SW-STD (MR=0.96,95% CI 0.70-1.30). Using a Cox regression analysis 
to adjust for sex, age and significant background factors (season and death of mother), mortality rates 
tended to be lower for male recipients of EZ-HT than for boys receiving SW-STD (MR=0*73, 95% CI 
050-1*11) and higher for girls receiving EZ-HT than for girls receiving SW-STD (MR=1-30, 95% CI 
0.81-2.09) (test of interaction between sex and vaccine, P=0.067). The tendency to reduced survival benefit 
for girls following receipt of high-titre measles vaccines substantiated observations from randomized trials 
in Guinea-Bissau, Senegal and Haiti. Existing data provide little support for the notion that high-titre vac- 
cine is deleterious but it may not have the same beneficial effects as standard-titre measles vaccine. 
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Introduction 
Recent randomized vaccine trials in Guinea-Bissau 
(AABY et al., 1993a) and Senegal (AABY et al., 1991,1994) 
have identified lower survival rates due to increased 
non-measles mortality in females receiving high-titre 
(3104'7 infectious particles/dose) Edmonston-Zagreb 
(EZ-HT) and Schwarz (SW-HT) vaccines at less than 9 
months of age, compared to those receiving standard 
titre (approximately lo4'' infectious particles/dose) 
Schwarz (SW-STD) measles vaccine at 9-10 months of 
age. Studies in Haiti have similarly suggested that high- 
titre vaccines were associated with higher mortality 
among girls than medium-titre vaccines (HOLT et al., 
1993). Since the observation of decreased survival among 
female recipients of high-titre measles vaccines in 
the randomized trials was highly unexpected and has 
implications for immunization policies (EPI, 1990, 
1992), we have further examined mortality patterns 
for girls and boys who received EZ-HT or SW-STD 
vaccines in a routine immunization programme in a 
rural area of Senegal where we have previously con- 
ducted a trial of high-titre measles vaccines (AABY et 
al., 1991, 1994). 
Subjects and Methods 
Background 
The Sereer population of Niakhar in Senegal, the 
demographic surveillance system (GARENNE et al., 1987), 
and the epidemiology of measles in the study area 
(GARENNE & AABY, 1990; SAMB et al., 1993), have been 
described in detail elsewhere. Since 1987, the demo- 
graphic monitoring system has been based on annual 
censuses and weekly surveillance visits to all compounds 
during which information has been collected on migra- 
tion, marriages, births, deaths, vaccinations, breast feed- 
ing, and infections. 
A trial with high-titre measles vaccine was carried out 
in the Naikhar area between 1987 and 1989. This trial 
included children born from February 1987 to January 
1989 (AABY et al., 1991,1994; SAMB et al., 1993). 
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Post-trial period: use of measles vaccines 
The present study included all 2396 children born to 
resident mothers in the 2 years following the completion 
of the high-titre trial; i.e., children born from February 
1989 through to January 1991. After the high-titre study, 
EZ-HT was used as the routine measles vaccine in the 
study area, except for children bom in February 1989 
who did not receive EZ-HT due to its unavailability 
(Table 1). The first monthly cohort received EZ-HT at 




Date of birth Type of vaccineb (months) 
February 1989 SW-STD, YF, 9-10 
DTP-IPV 
March-June 1989 EZ-HT, 
DTP-IPV 
5 
July 1989-April 1990 EZ-HT, YF, 6-7 
DTP-IPV 
May 1990-January 1991 SW-STD, YF, 
aAll groups were followed until February 1994. 
bDTP=diphtheria-tetanus-pertussis; EZ-HT=Edmon- 
ston-Zagreb high-titre; IPV=inactivated poliovirus; 
SW-STD=Schwarz standard; YF=yellow fever. 
9-10 
DTP-IPV 
5 months of age. Subsequently, children were vaccinated 
with EZ-HT at 6-7 months of age as part of a pertussis 
vaccine trial conducted in the area. EZ-HT was admin- 
istered together with diptheria-tetanus-pertussis/inacti- 
vated poliovirus vaccine (DTP-IPV), usually the third 
dose, and yellow fever vaccine. Some children received 
the 3 doses of DTP-IPV at 2, 4 and 6 months of age, 
whereas others missed one session and received the third 
dose at 7 months. Throughout the entire EZ-HT period, 
children who did not attend when first called for measles 
immunization were subsequently offered EZ-HT (41%) 
or SW-STD (59%) measles vaccines. When EZ-HT vac- 
cine was discontinued in November 1990, after 14 
months of total use, SW-STD administered at 9-10 
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months of age was reintroduced as the routine measles 
vaccine in the study area (Table l), and was used for the 
remaining 9 monthly cohorts encompassed in the fol- 
low-up. 
Mothers of children living in the study area were ad- 
vised by field assistants to attend the monthly vaccina- 
tion session in their district when their children reached 
the appropriate age. Those who followed the invitation 
and received measles vaccine and those who did not 
come have been called attenders and non-attenders, re- 
spectively. Many of the non-attenders received measles 
immunization during subsequent vaccination campaigns 
in the study area. 
Vaccine efficacy 
Efficacy of both EZ-HT and SW-STD after 9 months 
of age was assessed by comparing secondary attack rates 
among children exposed to measles infection within 
their compound of residence who had not had measles 
Table 2. Secondary attack rates and vaccine efficacy 
among children according to intensity of exposure and 
type of measles vaccine; Niakhar, Senegal, 1989-1993 
Secondary attack rates 
Exuosure ;EZ-HTa SW-STDa No vaccine 
Compound 5% (1/20) 0% (0/18) 42% (5/12) 
Household : 4% (1/23) 3% (1/30) 46% (6/13) 
Hut ' 2% (1/53) 6% (2/32) 63% (15/24) 
Total 3% (3/96) 4% (3/80) 53% (26/49) 
aEZ-HT=Edmondston-Zagreb high-titre measles vac- 
Vaccine &4% (81-98%) 93% (77-98%) - 
efficacy 
cine; SW-STD=Schwarz standard measles vaccine. 
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and non-attenders. In this analysis, non-attenders later 
immunized against measles were excluded from the 
analysis from the time of measles immunization. Mortal- 
ity was also compared for attenders who received, re- 
spectively, EZ-HT at 5-7 months and SW-STD at 9-10 
months. Though not allocated at random to the 2 
groups, these children shared the selection bias of hav- 
ing attended and received measles vaccine. 
Since SW-STD was administered only from 9 months 
of age, the comparison was based on follow-up after each 
child reached 9 months (>273 d) of age. Children who 
died or migrated before reaching the recommended age 
for vaccination were not considered. Children resident 
at the time of planned measles immunization were fol- 
lowed to death, migration, or 10 February 1994, the first 
date of the annual census in 1994. The survival status of 
all children still living in the study area was examined 
individually at the annual follow-up in February 1994. 
Pooled estimates were obtained using the method of 
maximum likelihood (ROTHMAN, 1986). Variation in sex 
mortality ratios was assessed by a likelihood ratio test. 
In the comparison of children receiving EZ-HT and 
SW-STD, a Cox regression model (COX, 1972) was used 
to adjust for possible confounding background factors 
such as age, season at risk (rainy/dry), and death of 
mother. Age was used as the time scale in the model. Ef- 
fects are expressed as mortality ratios (MR) with appro- 
priate 95% confidence intervals (95% CI), based on 
maximum likelihood estimation. 
Results 
Study cliildren, coverage and measles infection 
When called for EZ-HT vaccination (5-7 months), 
72.1% of the eligible children (928/1287) received vac- 
cine. A similar proportion, 73.0% (609/834), received 
SW-STD when first called (9-10 months). Mean age at 
attendance was the same for boys and girls: 193 d for 
Table 3. Deaths per 1000 person-years at risk for vaccinated attenders and unvaccinated non-attenders according 
to type of measles vaccinea 
Type of vaccine Deaths/1000 PYRb Mortality ratioc 
and period evaluated Vaccinated Unvaccinated (unvaccinated/vaccinated) 
EZ-HTd (n=928) (n=359) 
9-23 months 443 (4W1084.1) 80.2 (19/237.0) 1.81 (1.06-3.08) 
24-35 months 45.0 (36/799.6) 31.3 (5/159-8) 0.70 (0'27-1.77) 
36-59 months 26.4 (27/1021.4) 38.5 (W207.7) 1.46 (0.66-3-21) 
Total 38.2 (111/2905.1) 52.9 (32/6045) 1.38 (0.93-2.04)e 
S W-STD f (71=609) (n=225) 
9-23 months 47.6 (33/693*0) 83.0 (15/180*8) 1.74 (0.95-3-21) 
24-35 months 447 (241537.4) 69.0 (8/116*0) 1.54 (0.69-3'44) 
36-59 months 28-9 (8/276-7) 17.0 (1/58*9) 0.59 (0-07-4-70) 
Total 43-1 (65/1507-1) 67.5 (24/355-7) 1.54 (0.97-2.47)' 
Children born in Niakhar, Senegal, between February 1989 and January 1991. 
bPYR=person-years at risk. 
c95% confidence interval in parentheses. 
dEdmonston-Zagreb high-titre, given at 5-7 months. 
eEstimate adjusted for age groups. 
fSchwarz standard, given at 9-10 months. 
previously. As in previous studies from the Niakhar area 
(GARENNE & AABY, 1990; SWB et al., 1993), we adjusted 
the analysis for intensity of exposure; i.e., exposure 
within the same hut, within the same household, or 
within the same compound. Information on exposure 
was obtained through the measles surveillance system in 
the study area. Previous studies have found that most 
cases of measles not detected by this system occurred 
outside the study area (SAMB et al,, 1993). 
Survival analyses 
Mortality rates, calculated as deaths in relation to per- 
son-years at risk (PYR), were compared for attenders 
those who received EZ-HT and 295 d for recipients of 
SW-STD. Forty-four unvaccinated and 6 vaccinated 
children in this cohort contracted measles; 2 of the un- 
vaccinated children died in the acute phase. 
Vaccine efficacy 
There was no difference in secondary attack rates after 
9 months of age among recipients of EZ-HT and 
SW-STD vaccines (Table 2). Compared with unimmu- 
nized children from the same cohort exposed at home, 
the vaccines had similar efficacy, EZ-HT 94% (95% CI 
81-98) and SW-STD 93% (95% CI 77-98). Efficacy did 
not differ by gender; for boys receiving EZ-HT it was 
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Table 4. Deaths per 1000 person-years at risk according to sex, age and vaccine typea 
Type of vaccine Deaths/1000 PYRb Mortality ratioC 
and age (months) Males Females (femalelmale) 
EZ-HTd (n =470) (n=458) 
9-23' 38.4 (2U546.2) 50.2 (27/537*9) 1.31 (0.74-2.31) 
24-35 47-0 (19/403.9) 43.0 (17/395.7) 0.91 (0'47-1.76) 
21.2 (11/517*9) 31.8 (16b03.4) 1.50 (0.69-3.22) 36-59 
Total 34.7 (51/1468.0) 41.8 (60/1437*0) 1.20 (0.83-1.74)f 
SW-STDg (n = 3 17) (n=292) 
9-23 58.2 (2U361.0) 36.1 (12/332*0) 0.62 (0.31-1.26) 
34.2 (9/263*1) 0.63 (0.27-1.43) 24-35 54.7 (15/274*3) 
36-59 28.4 (4D40.9) 29.5 (4/135.7) 1-04 (0.26-4.15) 
Total 51.5 (40/776*2) 34.2 (25/730*8) 0.67 (0.40-1 -1O)f 
Crudef 0.74 (0.49-1.13) 1-28 (040-2.06) 
Mortality ratio (EZ/SW-STD) 
Adiustedh 0.73 (0.50-1.11) 1.30 (0.81-2.09) 
Children born in Niakhar, Senegal, between February 1989 and January 1991. , 
bPYR=person-years at risk. 
c95% confidence interval in parentheses. 
dEdmonston-Zagreb high-titre, given at 5-7 months. 
eBetween 5 and 8 months of age, the mortality rates were 0.0694 (7/100.9) for males and 0.0797 (8/100.4) for females re- 
%stimate adjusted for age groups. 
gSchwarz standard, given at 9-10 months. 
hEstimate adjusted for age, season and death of mother. 
ceiving EZ-HT. 
96% (95% CI 70-99) VS. SW-STD 96% (95% CI 65-loo), 
and for girls EZ-HT 91% (95% CI 69-98) and SW-STD 
88% (95% CI 57-97). 
Mortality of attenders and non-attenders 
All surviving children were at least 3 years old at fol- 
low-up in February 1994. Non-attenders who were un- 
vaccinated tended to have higher age-adjusted mortality 
rates than those who received measles vaccination, irre- 
spective of whether the attenders were vaccinated with 
EZ-HT a t  5-7 months (Table 3). The tendency was the 
same for boys and girls (data not shown). Most of the ef- 
fect occurred between 9 and 23 months of age (Table 3). 
There was no difference in mortality after 9 months of 
age between non-attending children from the periods 
where EZ-HT and SW-STD were used routinely (ad- 
justed for age, MR=0.87, 95% CI 051-1-49) or between 
recipients of EZ-HT and SW-STD (MR=0.96,95% CI 
0.70-1.30) (Table 3). 
When analysed by sex of the child (Table 4), mortality 
rates after 9 months of age tended to be lower among 
male recipients of EZ-HT than among recipients of 
SW-STD (MR=0.74, 95% CI 0.49-1-13), while female 
recipients of EZ-HT tended to have a higher mortality 
rate than did female recipients of SW-STD (MR= 1.28, 
Tendencies were unchanged when a Cox regression 
model was used to adjust for sex, age and significant 
background factors, season (P=O.OOO), and death of 
mother (P=0-0067). Mortality of female recipients of 
EZ-HT was 1-30 (95% CI 0.81-2.09) times higher than 
that for girls receiving SW-STD, whereas there was a 
tendency in the other direction for boys (MR=0.73,95% 
CI 0.50-1-11) (test of interaction between sex and vac- 
cine: x2=3-34, 1 degree of freedom,P=0*067). 
Discussion 
Following the completion of several studies of high- 
titre vaccines (WHITTLE et al., 1988; TIDJANI et al., 1989; 
MARKOWITZ et al., 1990) and the trial in Niakhar, 
EZ-HT was introduced as the routine measles vaccine 
in the study area from mid-1989. In November 1990, 
EZ-HT was replaced by SW-STD. Even though it was 
95% CI 0.80-2.04). 
not a randomized study, we tried to analyse the vaccine 
efficacy and the mortality pattern associated with these 
vaccines. 
There was little measles in the post-trial cohort of 
children, as in the previous trials (AABY et al., 1991, 
1993a, 1994; SAMB et al., 1993), and no important differ- 
ence in vaccine efficacy was observed in any of these tri- 
als. Hence, lower efficacy of high-titre vaccines does not 
explain the higher mortality among girl recipients of 
such vaccines. 
We compared mortality of attenders coming for mea- 
sles vaccination when first called; these 2 vaccine groups 
presumably had common socio-economic and cultural 
characteristics. With non-attending children there was 
no significant difference in mortality between the peri- 
ods when EZ-HT and SW-STD were used. 
Both the EZ-HT and SW-STD groups had lower 
mortality rates than unvaccinated children. This differ- 
ence could reflect an inherent selection bias between at- 
tenders and non-attenders. However, during the pre- 
vious trial (AMY et al., 1994), 638 attenders who 
received DTP-IPV or placebo, but no measles vaccine, 
at 5 months of age tended to have a higher mortality rate 
between 5 and 10 months of age than did 607 non-atten- 
ders (MR=1.60, 95% CI 0.76-3.37) (AABY et al., 1995). 
Hence the markedly improved survival of recipients of 
EZ-HT compared with non-attenders is unlikely to re- 
flect simple selection bias and suggests that EZ-HT is 
better than no measles vaccine. This interpretation is 
also supported by the observation that the recipients of 
EZ-HT did not have a higher mortality rate between 5 
and 10 months of age than controls who had received a 
placebo but no measles vaccine (AABY et al., 1994). 
In  the post-trial period, EZ-HT was not associated 
with an increase in mortality compared with SW-STD. 
The data suggested, but did not prove, an interaction be- 
tween titre of measles vaccine and the sex-specific mor- 
tality pattern; girls receiving high- titre vaccine tended 
to have a higher mortality rate than those receiving 
standard doses, while boys receiving high-titre vac- 
cine had reduced mortality compared with those re- 
ceiving standard doses. A similar pattern of less sur- 
vival benefit among female recipients of high-titre 
F- 
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Schwarz and Edmonston-Zagreb vaccines was found 
consistently in the randomized trials (AABY et al., 1991, 
1993a, 1994; HOLT et al., 1993); survival of boys was 
remarkably similar after both high-titre and lower 
doses of measles vaccine. 
The difference in mortality rates between recipients of 
high-titre and standard-titre vaccines may be related to 
non-specific effects of measles vaccine, since there was 
no difference in vaccine efficacy. It has therefore been 
suggested that high-titre vaccines were associated with 
deleterious effects (HALSEY, 1993). Retrospective studies 
in both Bissau (LISSE et al., 1994) and Niakhar (SAMB et 
al., 1995) have found no sign of any major persistent im- 
munosuppression among recipients of EZ-HT which 
could explain differences in mortality. There was no in- 
dication of continuing excess mortality after 3-4 years of 
age in either Bissau (LISSE et al., 1994) or Senegal (AMY 
et al., in press). The theory of a deleterious effect of high- 
titre vaccines (HOLT et al., 1993; GARENNE, 1994) is also 
contradicted by the facts that high-titre vaccines were 
not associated with lower survival in areas with low 
childhood mortality (WHITTLE et al., 1990; DIAZ- 
ORTEGA et al., 1992; LEÓN et al., 1993) and that recipi- 
ents of high-titre vaccine did not have higher mortality 
rates than control children before the latter received 
standard Schwarz measles vaccine (AMY et al., 1993a, 
1994). 
Though the mechanism is not known, several studies 
have suggested that standard measles vaccine reduces 
morbidity an& mortality more than would be expected 
from the prevention of acute measles cases (AABY et al., 
1993b, 1995; DESGFCÉES DU LOÛ et al., 1995). These stud- 
ies have also suggested that the impact of measles immu- 
nization in reducing overall mortality is temporary, and 
varies by gender. The temporary character of the effect 
on mortality, also found in the present study (Table 3), 
supports the notion that measles immunization has im- 
portant non-specific beneficial effects. A beneficial effect 
of standard vaccine, rather than a deleterious effect of 
high-titre vaccine, would explain the lack of difference 
in mortality between recipients of high-titre and stand- 
ard-titre vaccines in areas with low childhood mortality, 
and the absence of excess mortality among children re- 
ceiving high-titre vaccine compared with unimmunized 
control children in areas with high childhood mortality. 
A beneficial effect of standard-titre vaccine for girls 
(AABY et al., 1993c; DESGRÉES DU L O Û  et al., 1995) may 
be one reason that female recipients of high-titre measles 
vaccines had lower survival rates than recipients of 
standard vaccine. 
The Global Advisory Group of the Expanded Pro- 
gramme on Immunization no longer recommends that 
high-titre measles vaccine be used in routine immuniza- 
tion programmes (EPI, 1992). Further studies into possi- 
ble mechanisms are clearly warranted (EPI, 1992) and as 
the same pattern was noted for girls receiving EZ-HT 
and SW-HT in both Senegal (AABY et al., 1994) and 
Haiti (HOLT et al., 1993), it appears that investigations 
should focus on the amount, rather than the type, of vaccine. 
Future trials of measles vaccine should consider the possi- 
bility of sex-specific and non-specific effects of vaccination. 
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